OGD 204

Drug Profile

OGD 204

Alternative Names: OGD204

Latest Information Update: 07 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OGD2 Pharma
  • Class Immunoconjugates
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 06 Sep 2016 OGD2 Pharma and Syndivia SAS agree to co-develop OGD 204 for Solid tumours and Cancers
  • 21 Jun 2016 Early research in Cancer in France (Parenteral) prior to June 2016
  • 21 Jun 2016 OGD2 Pharma and Green Cross LabCell agree on the development of Monoclonal antibodies against OAcGD2 for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top